Latest Interviews
Showing 1–13 of 13 transcripts.
Clear all filters- a16z21 min
7 More Healthy Years: What We Can Learn from Super Agers
The proposed healthcare strategy shifts focus from unproven aging reversal to preventing the "big three" age-related diseases through modifiable lifestyle factors and emerging medical technologies. By integrating personalized omics data, AI-driven risk profiling, and novel treatments like GLP-1 drugs and cellular therapies, this approach aims to extend healthspan by seven years for populations globally. This evidence-based framework prioritizes immediate disease mitigation over theoretical longevity, leveraging a 20-year incubation window to fundamentally redefine the standard of care.
- a16z29 min
AI at the Intersection of Bio | Vijay Pande, Surya Ganguli & Bowen Liu
Vijay Pande, Surya Ganguli, Bowen Liu
This event details the transformative shift in drug design from theoretical potential to operational reality, leveraging deep learning and massive protein sequence datasets to navigate the vast chemical space while addressing historical validation bottlenecks. By integrating single-cell foundation models and latent space theories, the discussion outlines strategies to overcome distributional generalization failures and reduce the 90% clinical trial failure rate through personalized medicine and optimized patient selection. Ultimately, the presentation projects a decade-long roadmap toward "digital human" simulation systems that aim to slash development costs and expand FDA-approved target coverage despite significant regulatory and interpretability hurdles.
- a16z35 min
Implementation, Data, Impact of Healthcare AI with Julie and Vijay
Industry leaders project that AI agents will reduce healthcare costs by up to 50% through labor arbitrage and prevention-focused value-based care, while simultaneously compressing training times from months to days. Despite these economic advantages, widespread adoption faces significant hurdles including regulatory ambiguity over AI credentialing, the inelastic nature of healthcare demand, and the critical need to shift from retrospective records to prospective data generation. To overcome these barriers, organizations are reclassifying technology as labor, utilizing AI as a recruitment tool to reduce clinician burnout, and transitioning toward hybrid models where human oversight manages complex exceptions while automated systems handle routine phenotyping and triage.
- a16z31 min
AI in Pharmaceutical R&D with Kim Branson
Kim Branson, GSK's Global Head of AI/ML, is driving a strategic initiative that creates a "sheltered bubble" to rapidly build AI capabilities before integrating them into the company's broader drug discovery workflow. His team currently leverages active learning loops and computational pathology to accelerate target identification and clinical trial optimization, achieving twentyfold reductions in screen times and enabling precise patient stratification. Branson emphasizes that the industry's primary bottleneck is access to longitudinal data with outcomes, positioning GSK to transition from simple algorithmic efficiency to a data-driven "juggernaut" defined by proprietary datasets and mechanistic biological integration.
- a16z38 min
Grand Challenges in Healthcare AI with Vijay Pande and Julie Yoo
Amidst a healthcare labor crisis and provider burnout, AI adoption is accelerating through administrative efficiencies in revenue cycle management and the digitization of complex payer-provider contracts. Strategic startups are targeting near-term opportunities by embedding natural language interfaces into existing Electronic Health Records, automating prior authorization, and restructuring clinical trials through real-world data analysis. While full-stack AI clinicians remain a distant goal, the immediate landscape prioritizes behavioral change strategies, unbundled care roles, and value-based care alignment to optimize patient outcomes and reduce systemic waste.
- a16z30 min
Fireside Chat with Sean Duffy
Amada Health, rebranding as Raising Health, recently celebrated reaching one million patients by leveraging a proprietary dataset of 25 million messages to deploy AI that augments care teams while addressing the limitations of GLP-1 medications through a dedicated lifestyle track. Co-founder Sean Duffy highlights how the company evolved from skepticism about "provider without clinics" into a foundational digital infrastructure that utilizes artificial empathy to mitigate provider shortages and lower long-term healthcare costs. By pivoting from pure software replication to a hybrid tech-life sciences model, the organization now positions itself as an essential "between-visit" partner capable of offloading longitudinal management from overwhelmed primary care clinicians.
- a16z22 min
Digital Biology with insitro's Daphne Koller
In-Citro, founded by Coursera co-creator Daphne Koller, is deploying a "data factory" model that uses CRISPR-edited human pluripotent stem cells to systematically generate genetic variance data for drug discovery. The company's proprietary POSH platform and multimodal biology language models analyze hundreds of millions of cells to identify disease mechanisms and predict therapeutic interventions, effectively replacing error-prone murine testing with human-derived systems. Koller aims to deliver a first tranche of medicines to patients by the end of the decade while extending this digital biology framework to address global challenges in agriculture and environmental sustainability.
- a16z44 min
Food, Drugs, and Tech: 100 years of Public Health
Established in 1906 to address public health crises, the FDA is currently transitioning its 20% GDP-regulated portfolio from legacy physical archives to a fully digital, data-informed infrastructure that leverages machine learning for food safety and pathogen tracking. While modernizing clinical trial frameworks through the 21st Century Cures Act to accommodate gene therapies and real-world evidence, the agency balances risk aversion with the urgent need to approve life-saving innovations like cell-cultured foods and AI-driven medical devices. This evolution positions the FDA to shift from reactive disease treatment to preventative longitudinal care, utilizing synthetic data and dynamic regulatory paradigms to manage emerging biological technologies over the next century.
- a16z21 min
AI is Industrializing Discovery
The speaker characterizes the current biotech era as an industrial revolution where AI is transforming drug discovery from a bespoke artisanal model into a scalable, engineering-driven process. By overcoming myths regarding biological complexity and data scarcity through techniques like graph convolutions and one-shot learning, companies are achieving accuracy rates of over 90% in biomarker discovery and predicting clinical outcomes with modest incremental gains. This strategic shift promises to slash manufacturing costs for protein therapeutics by up to 90% and reduce trial expenses, creating a critical opportunity for professionals to merge domain expertise with AI skills to industrialize discovery at unprecedented scale.
- a16z36 min
a16z Podcast | All About Synthetic Biology
James J. Collins, Vijay Pande, Hanne Tidnam, Hannah, Jim Collins
Emerging from a late 1990s pivot by biomedical engineers seeking to reverse-engineer biological networks, synthetic biology was formally launched in 2000 following the breakthrough construction of a genetic toggle switch by Jim Collins' lab alongside a repressilator by Michael Elowitz and Stan Leibler. The discipline has since evolved from academic skepticism into a hybrid industry balancing rational engineering design with directed evolution and machine learning, ultimately transitioning from failed bioenergy hype to a sustainable focus on high-value biomedicine, therapeutics, and educational programs like BioBits. Looking forward, the field is poised to deliver transformative applications ranging from programmable living therapeutics to environmental solutions like carbon-sequestering algae, bridging the gap between theoretical biology and practical utility over the coming decades.
- a16z36 min
a16z Podcast | Dark Data in Healthcare
Susannah Fox, Anil Sethi, Vijay Pande, Sonal Chokshi
A speaker outlines a paradigm shift in healthcare where the legal right of "Portability" under HIPAA transforms patients from passive data recipients into the central hubs of their own longitudinal medical records. This approach addresses the "dark data" gap by leveraging real-world evidence and AI to unify fragmented clinical and non-clinical sources, thereby accelerating chronic disease management and clinical trial matching. Ultimately, the proposal envisions a "permissionless innovation" ecosystem where frictionless data access empowers patients to coordinate care across providers and drive collaborative research.
- a16z27 min
a16z Podcast | Shifting Risk Mindsets, From Tech to Bio
Vijay Pande, Jorge Conde, Jeff Low, Jeffrey Lowe
This event guides tech founders through the critical challenges of translating their innovations into the biotechnology sector, emphasizing the necessity of treating biotech firms as data-driven enterprises. It details strategies to avoid operational pitfalls like "death by a thousand pilots" and outlines structural frameworks, such as LLC ring-fencing, to protect platform value while developing proprietary assets. Furthermore, the session provides actionable insights on diagnostics reimbursement, early validation "kill tests," and aligning hybrid investor syndicates to ensure sustainable growth in a high-barrier market.
- a16z22 min
a16z Podcast | When (and How) Biology Becomes Engineering
The event details the transformative shift in biology from a stochastic, discovery-based science to a standardized engineering discipline that treats biological components as predictable, interchangeable parts. Interdisciplinary innovation and machine learning now drive this transition by enabling repeatable design-build-refine cycles that replace traditional high-risk experimentation with data-driven predictability. This engineering mindset aims to commercialize biological platforms through measurable success rates and sustainable infrastructure, ultimately making previously impossible medical and industrial goals achievable through compounding technological improvements.